Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so ...

The basis for good science is diverse teams Novartis' culture of diversity and inclusion is crucial for the innovative excellence of our teams. It brings different perspectives, experiences, and ...

Careers at Novartis in Slovenia At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to ...

The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult ...

Albania Algeria Angola Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bolivia Bosnia and Herzegovina Brazil Bulgaria Burkina Faso ...

Phase 1: Patients with positive uptake of 68Ga-FAP- 2286 will receive a fixed dose of 177Lu-FAP-2286 IV administered every 6 weeks for a maximum of 6 doses. Doses range between 3.7 and 9.25 GBq ...

Apply for the Novartis scholarships for the 2025/2026 school year! Open to high school pupils and final-year university students in pharmacy, chemistry, biotechnology, engineering, and more. Gain ...

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on ...

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus ...

Study Description The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to ...

Study Description In the phase I part, to determine the recommended doses (RD) and dosing regimens of \ [177Lu\]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing ...